Prelude Capital Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $263K | Buy |
+1,558
| New | +$231K | 0.02% | 844 |
|
|
2026
Q1 | – | Sell |
-1,808
| Closed | -$256K | – | 1464 |
|
|
2025
Q4 | $256K | Buy |
+1,808
| New | +$262K | 0.02% | 873 |
|
|
2025
Q2 | – | Sell |
-2,132
| Closed | -$236K | – | 1231 |
|
|
2025
Q1 | $236K | Buy |
+2,132
| New | +$270K | 0.02% | 827 |
|
|
2022
Q4 | – | Sell |
-1,948
| Closed | -$207K | – | 1512 |
|
|
2022
Q3 | $207K | Buy |
+1,948
| New | +$198K | 0.01% | 1063 |
|
|
2020
Q4 | – | Sell |
-1,538
| Closed | -$148K | – | 1739 |
|
|
2020
Q3 | $148K | Buy |
1,538
+1,473
| +2,266% | +$170K | 0.01% | 776 |
|
|
2020
Q2 | $8K | Buy |
+65
| New | +$7.18K | ﹤0.01% | 1620 |
|
|
2019
Q2 | – | Sell |
-498
| Closed | -$44K | – | 1982 |
|
|
2019
Q1 | $44K | Buy |
498
+259
| +108% | +$21.6K | ﹤0.01% | 1156 |
|
|
2018
Q4 | $17K | Sell |
239
-11,805
| -98% | -$1.13M | ﹤0.01% | 1270 |
|
|
2018
Q3 | $1.48M | Sell |
12,044
-3,141
| -21% | -$356K | 0.09% | 262 |
|
|
2018
Q2 | $1.49M | Sell |
15,185
-3,553
| -19% | -$318K | 0.09% | 229 |
|
|
2018
Q1 | $1.55M | Buy |
18,738
+4,033
| +27% | +$341K | 0.11% | 174 |
|
|
2017
Q4 | $1.14M | Sell |
14,705
-28,554
| -66% | -$1.95M | 0.09% | 231 |
|
|
2017
Q3 | $2.65M | Buy |
43,259
+9,241
| +27% | +$488K | 0.24% | 88 |
|
|
2017
Q2 | $1.56M | Buy |
34,018
+13,493
| +66% | +$654K | 0.15% | 143 |
|
|
2017
Q1 | $889K | Buy |
20,525
+3,699
| +22% | +$158K | 0.09% | 251 |
|
|
2016
Q4 | $651K | Sell |
16,826
-11,560
| -41% | -$523K | 0.08% | 275 |
|
|
2016
Q3 | $1.44M | Buy |
28,386
+21,825
| +333% | +$1.09M | 0.15% | 151 |
|
|
2016
Q2 | $298K | Sell |
6,561
-500
| -7% | -$23K | 0.04% | 395 |
|
|
2016
Q1 | $279K | Buy |
7,061
+367
| +5% | +$14.6K | 0.04% | 433 |
|
|
2015
Q4 | $379K | Sell |
6,694
-1,400
| -17% | -$71.2K | 0.06% | 345 |
|
|
2015
Q3 | $322K | Buy |
8,094
+6,794
| +523% | +$328K | 0.05% | 404 |
|
|
2015
Q2 | $62K | Buy |
1,300
+800
| +160% | +$33.9K | 0.01% | 1073 |
|
|
2015
Q1 | $20K | Buy |
+500
| New | +$17.9K | ﹤0.01% | 1747 |
|
|
2014
Q4 | – | Sell |
-2,500
| Closed | -$47.4K | – | 2069 |
|
|
2014
Q3 | $39K | Sell |
2,500
-5,000
| -67% | -$74.7K | 0.01% | 1475 |
|
|
2014
Q2 | $111K | Sell |
7,500
-13,700
| -65% | -$193K | 0.01% | 1058 |
|
|
2014
Q1 | $341K | Buy |
+21,200
| New | +$363K | 0.05% | 545 |
|
|
2013
Q4 | – | Sell |
-1,500
| Closed | -$14.6K | – | 1803 |
|
|
2013
Q3 | $17K | Buy |
+1,500
| New | +$20.6K | ﹤0.01% | 1228 |
|
Other funds holding NBIX
Prelude Capital Management's NBIX Position: Q2 2026 in Review
Prelude Capital Management opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 1,558 shares worth $263K. The stake represents 0.02% of the portfolio and ranks #844 among its holdings. This is a return to the name: Prelude Capital Management previously reported a position in NBIX as recently as Q4 2025.
Prelude Capital Management first reported a position in NBIX in Q3 2013 and has held it in 27 quarters since. The position peaked at $2.65M in Q3 2017. 775 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.
- Prelude Capital Management held 1,558 shares of Neurocrine Biosciences worth $263K as of Q2 2026.
- Neurocrine Biosciences was a new Prelude Capital Management position in Q2 2026.
- Neurocrine Biosciences made up 0.02% of Prelude Capital Management's portfolio in Q2 2026, its #844 holding.
- Prelude Capital Management first reported a position in Neurocrine Biosciences in Q3 2013 and has held it in 27 quarters since.
- Prelude Capital Management's Neurocrine Biosciences position peaked at $2.65M in Q3 2017.
- 775 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.
Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.